TIL Expansion Using Adenosine A2aR Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding tumor-infiltrating lymphocytes (TILs) for cancer treatment are inefficient and costly, with limited success in improving clinical responses and widespread application due to the challenges of overcoming adenosine's immunosuppressive effects in the tumor microenvironment.
Innovation Solution
A method involving the use of adenosine A2A receptor antagonists, such as vipadenant, in combination with IL-2 and OKT-3, to rapidly expand TILs in a closed system, resulting in a significant increase in TIL numbers and a shift towards effector and central memory T cells, enhancing their therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional IL-2-based TIL expansion methods are used, then TILs can be expanded for cancer therapy, but the expansion is slow and inefficient due to adenosine's immunosuppressive effects in the tumor microenvironment
Solution Approach 1:
The patent converts the harmful immunosuppressive effect of adenosine into a beneficial outcome by using A2A receptor antagonists to block adenosine's negative effects. This allows the expansion process to overcome the tumor microenvironment's immunosuppression rather than being hindered by it, transforming a previously problematic factor into an opportunity for improved TIL expansion efficiency and clinical response
Solution Approach 2:
The patent changes the biochemical parameters of the expansion system by introducing A2A receptor antagonists (such as vipadenant, ciforadenant, SCH58261, SYN115, ZM241385, SCH420814) to the culture medium. This parameter change blocks adenosine signaling and creates optimal conditions for rapid TIL proliferation, achieving expansion rates that are significantly faster than traditional methods while maintaining high functional quality
2Adaptability or versatility
If TIL expansion therapy is applied to bulky, refractory cancers, then treatment options are available for poor prognosis patients, but the method is complex and costly with limited widespread application
Solution Approach 1:
The patent creates a universal expansion protocol using A2A receptor antagonists that can be applied across multiple cancer types and clinical scenarios. The method works for both bulky, refractory cancers and other tumor types, eliminating the need for complex selection processes. This multi-functional approach makes the therapy broadly applicable while simplifying the overall treatment workflow
Solution Approach 2:
The patent performs preliminary blocking of adenosine A2A receptors during the expansion process itself, rather than requiring separate pre-treatment or post-treatment steps. The A2A antagonist is incorporated into the expansion medium from the start, allowing the TILs to be expanded with inherently enhanced anti-tumor functionality already built-in, reducing overall treatment complexity
3Quantity of substance
If adenosine A2A receptor antagonists are used during TIL expansion, then TIL numbers increase rapidly and functional quality improves, but the cost of therapy increases due to additional drugs
Solution Approach 1:
The patent maintains continuous presence of A2A receptor antagonists throughout the entire expansion process, ensuring uninterrupted blocking of immunosuppressive signals. This continuous action maximizes TIL proliferation efficiency and functional quality throughout the culture period, achieving high yields that can reduce the number of expansion cycles needed, thereby offsetting the additional drug cost through improved efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively expands TILs, overcoming the immunosuppressive tumor microenvironment, leading to a higher therapeutic potential for cancer treatment by increasing TIL numbers and improving their functional subsets, thus enhancing treatment efficacy.
Implementation Method 1
A2A receptor (A2AR) antagonists are thus of interest as a novel form of checkpoint blockade for cancer immunotherapy
Implementation Method 2
performing an initial expansion of the first population of TILs in a first cell culture medium to obtain a second population of TILs, wherein the first cell culture medium comprises IL-2
Implementation Method 3
performing a rapid expansion of the second population of TILs in a second cell culture medium to obtain a third population of TILs, wherein the second cell culture medium comprises IL-2, OKT-3 (anti-CD3 antibody)
Data Source
AI summary
Methods of expanding tumor infiltrating lymphocytes (TILs) in the presence of an adenosine A2A receptor (A2aR) antagonist, such as vipadenant, CPI-444 (ciforadenant), SCH58261, SYN115, ZM241385, SCH420814, a xanthine superfamily A2aR antagonist, or related adenosine receptor 2A antagonist, and uses of expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, therapeutic combinations of TILs and A2aR antagonists, including compositions and uses thereof in the treatment of diseases such as cancer are disclosed herein.